NovoCure reports Q2 revenue growth of 15.6% year-over-year, exceeding analyst expectations by $11.16M.
NovoCure posted a Q2 GAAP loss per share of $0.13, beating estimates by $0.20. Revenue reached $183.6 million, up 15.6% from the same period last year and $11.16 million above consensus.
The company updated its full-year 2026 guidance, projecting total net revenue between $710 million and $725 million. Prior-year revenue stood at $614.8 million, reflecting continued growth in its oncology treatment portfolio.
Shares showed limited immediate reaction following the release, as investors digested the mixed earnings performance against revenue gains.